Form 8-K Editas Medicine, Inc. For: Jun 09
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07.Submission of Matters to a Vote of Security Holders
The Company held its Annual Meeting of Stockholders on June 9, 2022. The following is a summary of matters voted on at that meeting.
| 1. | The Company’s stockholders elected Jessica Hopfield, Ph.D., Emma Reeve, and David T. Scadden, M.D. to serve as Class III directors until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class III directors were as follows: |
| Votes For |
| Votes Withheld |
| Broker Non-Votes | |
Jessica Hopfield, Ph.D. |
| 19,767,030 | 12,183,467 | 15,556,933 | ||
Emma Reeve |
| 31,507,586 | 442,911 | 15,556,933 | ||
David T. Scadden, M.D. | 25,126,253 | 6,824,244 | 15,556,933 |
| 2. | The Company’s stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: |
Votes For |
| Votes Against |
| Votes Abstaining |
| Broker Non-Votes |
27,094,152 | 4,523,649 | 332,696 | 15,556,933 |
| 3. | The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such ratification were as follows: |
Votes For |
| Votes Against |
| Votes Abstaining |
| Broker Non-Votes |
47,078,968 | 261,279 | 167,183 | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||
|
| ||||
Date: | June 13, 2022 | By: | /s/ Gilmore O’Neill | ||
|
|
| Gilmore O’Neill | ||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Editas Medicine (EDIT) to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline
- Geopolitical Unrest Generates an Onslaught of DDoS Attacks, According to the Latest NETSCOUT Threat Intelligence Report
- Decarbonization Partners Exceeds Fundraising Target With US$1.40 Billion Final Close for Inaugural Fund
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
